CELLECTAR BIOSCIENCES INC(NASDAQ:CLRB) stock News

CLRB Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

a month ago - By: Benzinga - Mentions: GOVX SNGX LIXT OGEN ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

a month ago - By: Benzinga - Mentions: DYN APDN AXGN MLSS ...

12 Health Care Stocks Moving In Monday's After-Market Session

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

a month ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

2 months ago - By: Zacks Investment Research - Mentions: ANIX

Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

2 months ago - By: Cellectar Biosciences, Inc.

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

2 months ago - By: Zacks Investment Research - Mentions: PODD MGNX ALUR

CELLECTAR BIOSCIENCES INC (CLRB) Stock News

CLRB Latest News, Press Relases and Analysis

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

12 Health Care Stocks Moving In Tuesday's Intraday Session

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

12 Health Care Stocks Moving In Monday's After-Market Session

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies